Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsBrittany Craiglow, MD
Associate Professor Adjunct - DermatologyAbout
Research
Publications
2025
Successful Treatment of Alopecia Areata With One JAK Inhibitor After Failure of Other JAK Inhibitors
Kalil L, Craiglow B, King B. Successful Treatment of Alopecia Areata With One JAK Inhibitor After Failure of Other JAK Inhibitors. JAMA Dermatology 2025, 161: 1285-1287. PMID: 41060634, PMCID: PMC12509074, DOI: 10.1001/jamadermatol.2025.3537.Peer-Reviewed Original ResearchBaricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Passeron T, Arkin L, Ohyama M, Vleugels R, Senna M, Dutronc Y, Chestnut Colvin S, Das T, Sontag A, Somani N, Craiglow B. Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s660. DOI: 10.25251/1g590e41.Peer-Reviewed Original ResearchPhase 3 trialSALT scoreAlopecia areataSevere AAPrimary endpointSevere alopecia areataJanus kinase inhibitorsBenefits of early interventionPediatric subjectsKinase inhibitorsSevere diseaseResponse ratePatientsBL characteristicsPlaceboCharacteristics of adolescentsAreataBaricitinibEarly interventionBaselineEndpointAdolescentsEfficacyAdultsDiseaseDiscontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
Ogbutor C, Chen L, Kalil L, Kelley K, Craiglow B, King B, Senna M. Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series. International Journal Of Women's Dermatology 2025, 11: e218. PMID: 40810112, PMCID: PMC12348381, DOI: 10.1097/jw9.0000000000000218.Peer-Reviewed Original ResearchTreatment of Short Anagen Syndrome With Low‐Dose Oral Minoxidil
Francis N, Craiglow B. Treatment of Short Anagen Syndrome With Low‐Dose Oral Minoxidil. Pediatric Dermatology 2025 PMID: 41001993, DOI: 10.1111/pde.70049.Peer-Reviewed Original Research65063 Characterization of treatment, disease burden, and patient-reported outcome measures in a real-world cohort of patients with alopecia areata: the CorEvitas Alopecia Areata Registry
Senna M, Craiglow B, Malley W, Wahl P, McLean R, King B. 65063 Characterization of treatment, disease burden, and patient-reported outcome measures in a real-world cohort of patients with alopecia areata: the CorEvitas Alopecia Areata Registry. Journal Of The American Academy Of Dermatology 2025, 93: ab144. DOI: 10.1016/j.jaad.2025.05.576.Peer-Reviewed Original Research61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program
Mostaghimi A, Mayo T, Craiglow B, Goh C, Murage M, Ball S, Dabbous F, Kawata A, Somani N, Tosti A. 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program. Journal Of The American Academy Of Dermatology 2025, 93: ab132. DOI: 10.1016/j.jaad.2025.05.531.Peer-Reviewed Original Research62923 Patient Preferences for the Treatment of Alopecia Areata
Craiglow B, Senna M, Mesinkovska N, Harshaw Q, Deering K, Shaikh A, Barghout V, Cassella J, Ferro T. 62923 Patient Preferences for the Treatment of Alopecia Areata. Journal Of The American Academy Of Dermatology 2025, 93: ab68. DOI: 10.1016/j.jaad.2025.05.274.Peer-Reviewed Original ResearchStatement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
Meah N, Li J, Wall D, York K, Bhoyrul B, Bokhari L, Coulthard L, Asfour L, Abraham L, Asz‐Sigall D, Bergfeld W, Betz R, Blume‐Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Dlova N, Donovan J, Doroshkevich A, Eisman S, Farrant P, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Kossard S, Lee J, Lee W, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Roberts J, Rudnicka L, Saceda‐Corralo D, Shapiro J, Sharma P, Silyuk T, Suchonwanit P, Takwale A, Tosti A, Visser W, Vañó‐Galván S, Vogt A, Wade M, Yip L, Zlotogorski A, Zhou C, Sinclair R. Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024. Journal Of The European Academy Of Dermatology And Venereology 2025 PMID: 40698981, DOI: 10.1111/jdv.20833.Peer-Reviewed Original ResearchFrontal fibrosing alopeciaPrognostic indicatorIncidence of frontal fibrosing alopeciaOptimal treatment algorithmEvidence-based treatment recommendationsThree-round Delphi processInternational consensus statementSystemic therapyTreatment algorithmTreatment modalitiesPhysical therapyTreatment recommendationsConsensus statementDelphi processRobust researchExpert consensusConsensus thresholdDisease monitoringConsensus agreementTherapyCOLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
O'Connor C, Boyle A, Asfour L, Bhoyrul B, Bokhari L, Cotsarelis G, Cotter C, Craiglow B, Cutlar L, Dhurat R, Dlova N, Doche I, Donovan J, Drucker A, Eisman S, Melo D, Harries M, Hordinsky M, Kazmi A, King B, Kolios A, Meah N, Mirmirani P, Mostaghimi A, Ohyama M, Ovcharenko Y, Pirmez R, Piraccini B, Rudnicka L, Saceda‐Corralo D, Shapiro J, Sibbald C, Sinclair R, Smith B, Starace M, Vaño‐Galván S, Koh W, York K, McDonald I, Wall D. COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists. JEADV Clinical Practice 2025, 4: 811-820. DOI: 10.1002/jvc2.70067.Peer-Reviewed Original ResearchJanus kinase inhibitorsComplete blood countAlopecia areataSystemic therapySeverity of Alopecia ToolConventional systemic therapiesThyroid function testsComplete blood count testDermatology Life Quality IndexNon-scarring alopeciaLife Quality IndexLaboratory testsHair loss disorderHair specialistThrombophilia screeningLaboratory testing practicesCoagulation profileTreating AAHair expertsHepatitis BThyroid functionAutoimmune conditionsBlood countBlood testsKinase inhibitorsUnderstanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib
Mostaghimi A, Craiglow B, King B, Shapiro J, Ko J, Tosti A, Ohyama M, Brogan Y, Yu G, Sontag A, Somani N. Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib. British Journal Of Dermatology 2025, 193: 240-249. PMID: 40179237, DOI: 10.1093/bjd/ljaf088.Peer-Reviewed Original ResearchBaricitinib 4 mgBaricitinib 2 mgHair-bearing sitesAlopecia areataResponse rateBenefit of baricitinibTreated with baricitinibRandomised to placeboPlacebo-controlled trialResponse to treatmentScalp hair lossSALT scoreDouble-blindClinical presentationBaricitinib treatmentTreatment successHair regrowthBaricitinibBaseline severityPatientsClinician reportsHair lossPlaceboPooled dataScalp